The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis - ScienceDirect
Gavin Giovannoni, aka Prof G on X: "Just received this letter from Novartis UK. This is what happens when drugs go generic, i.e. support services disappear. We are told the switch from
JPM | Free Full-Text | Update on Multiple Sclerosis Molecular Biomarkers to Monitor Treatment Effects
Brain Sciences | Free Full-Text | Digital Biomarkers in Multiple Sclerosis
Multiple Sklerose: Besseres Monitoring, fundiertere Behandlungsentscheidungen
Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic | BMC Neurology | Full Text
Moderne MS-Medikamente – auch langfristig effektiv und sicher? – Rosenfluh.ch
MS Minute: Oral Therapies for MS - Practical Neurology
Neue Therapiemodalitäten
Starting RRMS Treatment | GILENYA® (fingolimod)
Diagnosis and Monitoring of Patients With Multiple Sclerosis - Practical Neurology
PDF) Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring
Safety Monitoring of Disease-Modifying Therapies in Multiple Sclerosis - Practical Neurology
Fall Assessment and Monitoring in People With Multiple Sclerosis | Neurology Clinical Practice
Starting RRMS Treatment | GILENYA® (fingolimod)
NDA 22-527 GILENYA (fingolimod) 0.5mg capsules RISK EVALUATION AND MITIGATION STRATEGY (REMS)
PDF) Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic
Untitled
Biosensing strategies (approaches) for diagnosis and monitoring of multiple sclerosis - ScienceDirect
Building a monitoring matrix for the management of multiple sclerosis - ScienceDirect
Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic | BMC Neurology | Full Text
